OAM
SRPT icon

OP Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

OP Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Buy
66,705
+56,709
+567% +$1.07M 0.01% 572
2026
Q1 		$218K Buy
+9,996
New +$193K ﹤0.01% 726

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

OP Asset Management's SRPT Position: Q2 2026 in Review

OP Asset Management increased its Sarepta Therapeutics (SRPT) stake by 567% in Q2 2026, buying an estimated $1.07M and bringing the position to 66,705 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #572.

OP Asset Management first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • OP Asset Management held 66,705 shares of Sarepta Therapeutics worth $1.2M as of Q2 2026.
  • OP Asset Management bought 56,709 Sarepta Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Sarepta Therapeutics made up 0.01% of OP Asset Management's portfolio in Q2 2026, its #572 holding.
  • OP Asset Management first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.